Skip to main content
Top
Published in: BMC Urology 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research article

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?

Authors: Kerri Beckmann, Netty Kinsella, Henrik Olsson, Anna Wallerstedt Lantz, Tobias Nordstrom, Markus Aly, Jan Adolfsson, Martin Eklund, Mieke Van Hemelrijck

Published in: BMC Urology | Issue 1/2019

Login to get access

Abstract

Background

Patient-related factors such as concern about cancer are believed to influence both men’s decisions to undergo prostate specific antigen (PSA) testing and to have definitive treatment if diagnosed with low risk prostate cancer (PCa). The potential link between screening frequency and choice of active surveillance (AS) for low risk disease has not been studied previously. Our aim was to investigate whether there is any association between PCa screening frequency or previous negative prostate biopsy and uptake of AS among men with low risk PCa.

Methods

This register-based study included all men ≤75 years from Stockholm who were diagnosed with low risk PCa from 2008 to 2014 (n = 4336). Pre-diagnostic PSA testing and biopsy histories were obtained from the Stockholm PSA and Biopsy Register, a population-based register for the Stockholm country. The association between previous screening/biopsy history and AS uptake (based on primary treatment recorded in the National Prostate Cancer Register) was examined using multivariable logistic regression.

Results

Forty seven percent of men with low risk PCa underwent AS. Uptake was associated with older age, very low risk disease, more recent diagnosis and absence of family history. None of the screening/biopsy measures (testing frequency, mean interval, PSA velocity, highest pre-diagnostic PSA or prior negative biopsy) were associated with uptake of AS among men with low risk PCa. Generalisability to settings with different policies and practices may be limited.

Conclusion

We found no evidence that screening frequency and negative biopsy influence uptake of AS among Swedish men with low risk PCa. Further research is required to determine factors that still present barriers for men taking up AS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171–84.CrossRef Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53(2):171–84.CrossRef
2.
go back to reference Hugosson J, Carlsson S. Overdetection in screening for prostate cancer. Curr Opin Urol. 2014;24(3):256–63.CrossRef Hugosson J, Carlsson S. Overdetection in screening for prostate cancer. Curr Opin Urol. 2014;24(3):256–63.CrossRef
3.
go back to reference Loeb S. Guideline of guidelines: prostate cancer screening. BJU Int. 2014;114(3):323–5.PubMed Loeb S. Guideline of guidelines: prostate cancer screening. BJU Int. 2014;114(3):323–5.PubMed
4.
go back to reference Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426–35.CrossRef Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426–35.CrossRef
5.
go back to reference Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232–7.CrossRef Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232–7.CrossRef
6.
go back to reference Klotz L. Active surveillance for low-risk prostate cancer. Curr Opin Urol. 2017;27(3):225–30.CrossRef Klotz L. Active surveillance for low-risk prostate cancer. Curr Opin Urol. 2017;27(3):225–30.CrossRef
7.
go back to reference Auffenberg GB, Lane BR, Linsell S, Cher ML, Miller DC. Practice- vs physician-level variation in use of active surveillance for men with low-risk prostate Cancer: implications for collaborative quality improvement. JAMA Surg. 2017;152(10):978–80.CrossRef Auffenberg GB, Lane BR, Linsell S, Cher ML, Miller DC. Practice- vs physician-level variation in use of active surveillance for men with low-risk prostate Cancer: implications for collaborative quality improvement. JAMA Surg. 2017;152(10):978–80.CrossRef
8.
go back to reference Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate Cancer in Sweden. JAMA Oncol. 2017;3(10):1393–8.CrossRef Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate Cancer in Sweden. JAMA Oncol. 2017;3(10):1393–8.CrossRef
9.
go back to reference Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M. Factors influencing Men's choice of and adherence to active surveillance for low-risk prostate Cancer: a mixed-method systematic review. Eur Urol. 2018. Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M. Factors influencing Men's choice of and adherence to active surveillance for low-risk prostate Cancer: a mixed-method systematic review. Eur Urol. 2018.
10.
go back to reference Dall'Era MA. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015;25(3):272–6.CrossRef Dall'Era MA. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015;25(3):272–6.CrossRef
11.
go back to reference Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62(6):976–83.CrossRef Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62(6):976–83.CrossRef
12.
go back to reference van den Bergh RC, Korfage IJ, Bangma CH. Psychological aspects of active surveillance. Curr Opin Urol. 2012;22(3):237–42.CrossRef van den Bergh RC, Korfage IJ, Bangma CH. Psychological aspects of active surveillance. Curr Opin Urol. 2012;22(3):237–42.CrossRef
13.
go back to reference Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F, Team SC. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3):544–51.CrossRef Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F, Team SC. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3):544–51.CrossRef
14.
go back to reference Kotwal AA, Schumm P, Mohile SG, Dale W. The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. 2012;50(12):1037–44.CrossRef Kotwal AA, Schumm P, Mohile SG, Dale W. The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. 2012;50(12):1037–44.CrossRef
15.
go back to reference Consedine NS. Are we worrying about the right men and are the right men feeling worried? Conscious but not unconscious prostate anxiety predicts screening among men from three ethnic groups. Am J Mens Health. 2012;6(1):37–50.CrossRef Consedine NS. Are we worrying about the right men and are the right men feeling worried? Conscious but not unconscious prostate anxiety predicts screening among men from three ethnic groups. Am J Mens Health. 2012;6(1):37–50.CrossRef
16.
go back to reference Wade J, Rosario DJ, Howson J, Avery KN, Salter CE, Goodwin ML, Blazeby JM, Lane JA, Metcalfe C, Neal DE, et al. Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. BMC Health Serv Res. 2015;15:80.CrossRef Wade J, Rosario DJ, Howson J, Avery KN, Salter CE, Goodwin ML, Blazeby JM, Lane JA, Metcalfe C, Neal DE, et al. Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. BMC Health Serv Res. 2015;15:80.CrossRef
17.
go back to reference Wade J, Rosario DJ, Macefield RC, Avery KN, Salter CE, Goodwin ML, Blazeby JM, Lane JA, Metcalfe C, Neal DE, et al. Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol. 2013;31(33):4235–41.CrossRef Wade J, Rosario DJ, Macefield RC, Avery KN, Salter CE, Goodwin ML, Blazeby JM, Lane JA, Metcalfe C, Neal DE, et al. Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol. 2013;31(33):4235–41.CrossRef
18.
go back to reference Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K, et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer. 2010;102(9):1335–40.CrossRef Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K, et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer. 2010;102(9):1335–40.CrossRef
19.
go back to reference Mishra MV, Bennett M, Vincent A, Lee OT, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Showalter TN. Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. PLoS One. 2013;8(9):e68563.CrossRef Mishra MV, Bennett M, Vincent A, Lee OT, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Showalter TN. Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. PLoS One. 2013;8(9):e68563.CrossRef
20.
go back to reference Volk RJ, McFall SL, Cantor SB, Byrd TL, Le YC, Kuban DA, Mullen PD. It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology. 2014;23(4):467–72.CrossRef Volk RJ, McFall SL, Cantor SB, Byrd TL, Le YC, Kuban DA, Mullen PD. It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology. 2014;23(4):467–72.CrossRef
21.
go back to reference Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–25.CrossRef Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–25.CrossRef
22.
go back to reference Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–11.CrossRef Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–11.CrossRef
24.
go back to reference Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: the National Prostate Cancer Register of Sweden and prostate Cancer data base--a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.CrossRef Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: the National Prostate Cancer Register of Sweden and prostate Cancer data base--a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.CrossRef
25.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef
26.
go back to reference Cooperberg MR, Carroll PR. Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. JAMA. 2015;314(1):80–2.CrossRef Cooperberg MR, Carroll PR. Trends in Management for Patients with Localized Prostate Cancer, 1990-2013. JAMA. 2015;314(1):80–2.CrossRef
27.
go back to reference Weerakoon M, Papa N, Lawrentschuk N, Evans S, Millar J, Frydenberg M, Bolton D, Murphy DG. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate Cancer registry. BJU Int. 2015;115(Suppl 5):50–6.CrossRef Weerakoon M, Papa N, Lawrentschuk N, Evans S, Millar J, Frydenberg M, Bolton D, Murphy DG. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate Cancer registry. BJU Int. 2015;115(Suppl 5):50–6.CrossRef
28.
go back to reference Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, Urbach D, Finelli A. The uptake of active surveillance for the management of prostate cancer: a population-based analysis. Can Urol Assoc J. 2016;10(9–10):333–8.CrossRef Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, Urbach D, Finelli A. The uptake of active surveillance for the management of prostate cancer: a population-based analysis. Can Urol Assoc J. 2016;10(9–10):333–8.CrossRef
29.
go back to reference Taylor KL, Shelby R, Kerner J, Redd W, Lynch J. Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress. Cancer. 2002;95(5):1037–44.CrossRef Taylor KL, Shelby R, Kerner J, Redd W, Lynch J. Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress. Cancer. 2002;95(5):1037–44.CrossRef
30.
go back to reference Roumier X, Azzouzi R, Valeri A, Guillemin F, Fournier G, Cussenot O, Mangin P, Cormier L. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer. Eur Urol. 2004;45(3):280–5 author reply 285-286.CrossRef Roumier X, Azzouzi R, Valeri A, Guillemin F, Fournier G, Cussenot O, Mangin P, Cormier L. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer. Eur Urol. 2004;45(3):280–5 author reply 285-286.CrossRef
31.
go back to reference Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer Epidemiol Biomark Prev. 2006;15(2):228–37.CrossRef Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C, Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups: the fear factor. Cancer Epidemiol Biomark Prev. 2006;15(2):228–37.CrossRef
32.
go back to reference Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA. The role of MRI in active surveillance for prostate cancer. Curr Urol Rep. 2015;16(6):42.CrossRef Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA. The role of MRI in active surveillance for prostate cancer. Curr Urol Rep. 2015;16(6):42.CrossRef
Metadata
Title
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Authors
Kerri Beckmann
Netty Kinsella
Henrik Olsson
Anna Wallerstedt Lantz
Tobias Nordstrom
Markus Aly
Jan Adolfsson
Martin Eklund
Mieke Van Hemelrijck
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2019
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-019-0502-4

Other articles of this Issue 1/2019

BMC Urology 1/2019 Go to the issue